| Title |
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial
|
|---|---|
| Published in |
Annals of Hematology, November 2014
|
| DOI | 10.1007/s00277-014-2250-6 |
| Pubmed ID | |
| Authors |
Ines Wasle, Gabriele Gamerith, Florian Kocher, Patrizia Mondello, Thomas Jaeger, Alois Walder, Jutta Auberger, Thomas Melchardt, Werner Linkesch, Michael Fiegl, Michael Mian |
| Abstract |
The anthracycline doxorubicin plays a major role in the treatment of lymphoproliferative disorders. However, its use is often limited due to cardiac toxicity, which seems to be much less in the liposomal non-pegylated formulation (Myocet®). The aim of this study was the evaluation of efficacy and toxicity of Myocet®-containing treatment regimens, with a focus on cardiotoxicity during treatment in lymphoma patients. A total of 326 consecutive patients, treated between March 2008 and December 2013 in 11 Austrian and 1 Italian cancer centers, were retrospectively assessed. Patients' baseline and treatment-related parameters were obtained by reviewing hospital records. Median age was 74 years (range 26-93). The most common histology was DLBCL (60 %), followed by FL (13 %) and MCL (8 %). At least one cardiovascular comorbidity was present in 72 % of patients. Most common grade 3/4 toxicities were hematologic, namely, leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia in 44, 40, 17, and 16 %. Overall, 43 patients suffered a cardiac event (any grade) with most patients developing congestive heart failure. Parameters significantly associated with severe cardiac events (grades 3-5) were the presence of cardiovascular comorbidities, chronic obstructive pulmonary disease, and elevated baseline NT-proBNP. Treatment response after first line Myocet®-containing therapy was ≥58 % among all entities (range 58-86 %) and therefore comparable to those of conventional therapeutic regimens. Herein, we provide a detailed toxicity profile of Myocet®-containing chemotherapy regimens. Despite the high rate of patients with preexisting comorbidities, the number of adverse events was encouraging. However, these results need to be confirmed in a prospective randomized trial. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 29 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Student > Ph. D. Student | 6 | 19% |
| Student > Master | 4 | 13% |
| Student > Doctoral Student | 4 | 13% |
| Student > Bachelor | 3 | 10% |
| Other | 3 | 10% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Computer Science | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 3 | 10% |
| Unknown | 8 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2015.
All research outputs
#20,263,155
of 22,793,427 outputs
Outputs from Annals of Hematology
#1,702
of 2,164 outputs
Outputs of similar age
#215,996
of 258,764 outputs
Outputs of similar age from Annals of Hematology
#20
of 21 outputs
Altmetric has tracked 22,793,427 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,164 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,764 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.